Effectiveness of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia

Rákkutatás · Lymphoma

Integrated palliative and oncology care (IPC) improves quality of life, reduces depression, anxiety, and post‑traumatic stress symptoms, and increases end‑of‑life care discussions while decreasing aggressive chemotherapy near death in adults with acute myeloid leukemia.

This multicenter randomized clinical trial evaluated the impact of integrated palliative and oncology care (IPC) compared with usual care (UC) in 160 adults with acute myeloid leukemia (AML) undergoing intensive chemotherapy. Patients assigned to IPC were seen by palliative care clinicians at least twice per week during initial and subsequent hospitalizations. At week 2, IPC participants reported better quality of life (Mean 116.45 vs 107.59), lower depression (Mean 5.68 vs 7.20), lower anxiety (Mean 4.53 vs 5.94), and lower post-traumatic stress symptoms (Mean 27.79 vs 31.69) than UC participants. These benefits were maintained to week 24. Among patients who died, those in the IPC group were more likely to discuss end‑of‑life care preferences (75 % vs 40 %) and were less likely to receive chemotherapy in the last 30 days of life (34.9 % vs 65.9 %).

The findings support the adoption of integrated palliative care as a standard of care for patients with AML, improving patient‑centered outcomes and reducing aggressive end‑of‑life treatments.

Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.

Eredeti forrás

Kapcsolódó jelek